TD Cowen analyst Dan Brennan raised the firm’s price target on 10x Genomics (TXG) to $18 from $15 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies “already soft guided” 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $20 from $19 at Canaccord
- 10x Genomics price target raised to $18 from $15 at BofA
- 10x Genomics price target raised to $22 from $17 at Barclays
- 10x Genomics downgraded to Neutral from Buy at Citi
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls